Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation

Benjamin Bonnet, Justine Cosme, Claire Dupuis, Elisabeth Coupez, Mireille Adda, Laure Calvet, Laurie Fabre, Pierre Saint-Sardos, Marine Bereziat, Magali Vidal, Henri Laurichesse, Bertrand Souweine, Bertrand Evrard.

Service d’Immunologie, CHU Gabriel-Montpied, Clermont-Ferrand, France
Laboratoire d’Immunologie, ECREIN, UMR1019 UNH, UFR Médecine de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France
Service de Médecine Intensive et Réanimation, CHU Gabriel-Montpied, Clermont-Ferrand, France
Laboratoire de Bactériologie, CHU Gabriel-Montpied, Clermont-Ferrand, France
Service de Maladies Infectieuses et Tropicales, CHU Gabriel-Montpied, Clermont-Ferrand, France

ABSTRACT

Background: SARS-CoV-2 has been responsible for considerable mortality worldwide, owing in particular to pulmonary failures such as ARDS, but also to other visceral failures and secondary infections. Recent progress in the characterization of the immunological mechanisms that result in severe organ injury led to the emergence of two successive hypotheses simultaneously tested here: hyperinflammation with cytokine storm syndrome or dysregulation of protective immunity resulting in immunosuppression and unrestrained viral dissemination.

Methods: In a prospective observational monocentric study of 134 patients, we analysed a panel of plasma inflammatory and anti-inflammatory cytokines and measured monocyte dysregulation via their membrane expression of HLA-DR. We first compared the results of patients with moderate forms hospitalized in an infectious disease unit with those of patients with severe forms hospitalized in an intensive care unit. In the latter group of patients, we then analysed the differences between the surviving and non-surviving groups and between the groups with or without secondary infections.

Findings: Higher blood IL-6 levels, lower quantitative expression of HLA-DR on blood monocytes and higher IL-6/mHLA-DR ratios were statistically associated with the risk of severe forms of the disease and among the latter with death and the early onset of secondary infections.

Interpretation: The unique immunological profile in patients with severe COVID-19 corresponds to a moderate cytokine inflammation associated with severe monocyte dysregulation. Individuals with major CSS were rare in our cohort of hospitalized patients, especially since the use of corticosteroids, but formed a very severe subgroup of the disease.

Funding: None.

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Since the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan in 2019, the disease has spread very rapidly to become a global pandemic currently responsible for more than 4.5 million deaths. About 15% of coronavirus disease 2019 (COVID-19) patients over 60 years of age require hospitalization and 5% require intensive care unit (ICU) admission [1,2]. ICU mortality rate is high, ranging from 16 to 57%, and is mainly related to pulmonary complications of the acute respiratory distress syndrome (ARDS) [3–7]. Multiple organ failure (in 12 to 29% of cases) and secondary infections (in 10 to 57% of cases) can also frequently occur [3,8,9].

Understanding the pathophysiology of severe COVID-19 forms, especially of respiratory failure, is henceforth critical for determining the best management and treatment strategies. Recent progress in the characterization of the immunological mechanisms that result in organ injury, with particular regard to the determinants of severity, has shown the role of hyperinflammation, in particular elevated levels of proinflammatory cytokines or chemokines associated with anomalies of adaptive and innate immunity through disruption of the lymphoid and myeloid lineages [10–12].
CD8+ T cells towards a terminally differentiated/senescent phenotype

numbers of circulating T, B, and NK cells, exhibit activation of CD4 T

COVID-19 are associated with lymphopenia, including decreased

more complex cellular immune dysregulation. Severe forms of

injury to the organ [3,12


detailed description of the patient pro

nological characteristics of patients on both sides of the

spread and thus ARDS. Few studies have described the immu-
nological characteristics of patients on both sides of the

response simultaneously and did not provide a
detailed description of the patient profile based on the severity

of the disease or on the mortality induced. Furthermore, they
did not at all describe whether these markers were associated
or not with the occurrence of secondary infections. All these

would however be necessary to guide therapeutic
choices in a personalized medicine approach that would adapt
treatment to the inflammatory or immunocompromised profile
of the patients.

Added value of this study

Our data provide new evidence that patients with severe forms
of COVID-19 most often exhibit moderate cytokine inflamma-
tion concurrently with severe monocytic dysregulation. We
show that a quantitative decrease in mHLA-DR membrane
expression and an increase in the IL-6/mHLA-DR ratio were
associated with severe forms of the disease, the degree of pul-
monary involvement, and the risk of death and onset of early

infections. In addition, we show that patients with a major
cytokine storm were rare in our cohort of hospitalized patients,
especially since the systematic use of corticosteroids, but corre-
sponded to a subgroup of patients with a very poor prognosis.

Implications of all the available evidence

The mHLA-DR expression and the IL-6/mHLA-DR ratio could be
used in a routine care approach to identify patients at risk for
severe forms, death and early secondary infections. This could
make it possible to better adapt the therapies implemented in a
personalized medicine approach, using treatments that target
cytokine inflammation or, depending on the patient's profile,
immunostimulant treatments.

The first related studies posed the hypothesis of the cytokine
storm syndrome (CSS), suggesting that the increase in pro-inflamma-
tory cytokines (IL-2, IL-6, IL-7, IP-10, TNFα...), which is marked in
ICU patients and associated with impaired interferon type 1 response,
induced the infiltration of inflammatory cells in the lung and thus
injury to the organ [3,12–14]. However, this hypothesis has recently
been called into question, in particular by comparing the level of
increase in cytokines with that observed in other pathological situa-
tions that induce CSS, such as sepsis and CAR-T cell infusion, and
those that do not, such as influenza [15–17].

A new explanation is gradually emerging that places emphasis on
more complex cellular immune dysregulation. Severe forms of
COVID-19 are associated with lymphopenia, including decreased
numbers of circulating T, B, and NK cells, exhibit activation of CD4 T
cells and decrease regulatory T cells associated with a skewing of
CD8+ T cells towards a terminally differentiated/senescent phenotype

[18–21]. Deep analysis also revealed drastic changes within the mye-
loid cell compartments during severe COVID-19. With regard to neu-
rophils, multiple abnormalities have been described such as
increased neutrophil/lymphocyte ratio, evidence of emergency mye-
lopoiesis with release of immature neutrophils, transcriptional pro-
grams typical of dysfunction and immunosuppression, and lung
recruitment with NETosis [22–25]. Abnormalities of monocytes have
been recently characterized, where expansion and early activation of
classical monocytes (CD14+CD11c+HLA-DR+) in the blood are char-
acteristics of mild COVID-19 which decrease during the natural
course of the disease. In contrast, in severe forms the non-classical
monocyte subpopulation (CD14+CD16+) appears depleted, probably
due to its lung recruitment, and the intermediate (CD14+CD16+) and
classical subsets (CD14++CD16+) become dysfunctional with the loss of
HLA-DR membrane expression [11,18–21].

Here we hypothesize that the two phenomena described above,
 hyperinflammation or dysregulation of protective immunity, proba-
bly took place at the same time in the severe forms and were nega-
tively complementary rather than antagonistic. We therefore looked
for simple biological tools that are routinely available in our univer-
sity hospital centre to simultaneously test hyperinflammation, anti-
inflammatory cytokines and monocyte dysregulation by a panel of
plasma cytokines and by measuring the membrane expression of
human leukocyte antigen—antigen D-related (HLA-DR) on the surface
of monocytes. We initially chose this last marker because it is now a
recognized diagnostic marker in the assessment of the severity of
sepsis-induced immunosuppression [22]. We first sought to see if
these markers were capable of distinguishing between mild forms
observed in the hospital infectious disease unit (IDU) and ICU severe
forms. Focusing on the severe forms, we then sought to assess the
potential of these markers to 1) determine possible differences in the
immune profiles between patients of the two successive COVID-19
waves in France, 2) identify patients according to whether they had
fatal evolution or not, and 3) predict the risk of secondary infections
in order to provide evidence of the real immunoparessis of the
immune system.

2. Methods

2.1. Patients and data collection

All patients with confirmed COVID-19 admitted to the IDU medi-
cal wards and ICU of the Gabriel-Montpied Teaching Hospital in Cler-
mont-Ferrand, France, from March to the end of November 2020
were eligible for enrolment. A total of 134 patients admitted to the
ICU were thus included in a preliminary prospective monocentric
observational study and followed up until ICU discharge and/or
death. In our hospital, as in the rest of France, we experienced two
distinctly separate waves of patient hospitalizations: the months
of March to June (03/08/2020 to 06/02/2020), a period called Wave 1,
during which 34 patients were enrolled, and from September to
November (09/14/2020 – 11/23/2020), a period called Wave 2, dur-
ing which 99 others were included. A single patient was hospitalized
in August between the two waves, but for the purpose of the study
was included in the Wave 1 group. We decided therefore a posteriori
to analyse the data of ICU patients based on their period of hospitali-
zation, especially since the results of the RECOVERY clinical trial, pub-
lished in the summer of 2020, showed the clinical benefit of
dexamethasone on 28-day mortality in patients requiring oxygen
support. This led to a change in practice in the management of ICU
COVID-19 patients with the introduction of dexamethasone as soon
as the patient required oxygen [23].

The immunoactivation/immunosuppression balance was moni-
tored in the patients at three different time points, on days 0-3, days
7-10 and at ICU discharge (endpoint).
ICU admission data, ie demographic characteristics, comorbidities, severity score (SAPS II), nadir PaO2/FiO2 ratio, and laboratory findings were also collected (Table 1). During their ICU stay, patients were screened for nosocomial infections defined as microbiologically-proven pneumonia, complicated urinary tract infection (eg prostatitis), bacteremia, septic shock, catheter-associated infections and fungal infections. The survival status of included patients at discharge from the ICU was recorded. In terms of sample size, due to our pragmatic approach based on the interest in patients in daily care, we initially wanted to test all patients hospitalized in the IDU and ICU of our hospital without restrictive inclusion criteria to determine whether the markers chosen were predictive of the risk of worsening. However, this was not possible in practice for reasons of feasibility in a pandemic context that led to obstacles such as shortage of stocks of reagents and overwork of healthcare teams. Our aim at the outset was to include all patients hospitalized in the IDU as reference cases of mild-form COVID-19, which proved impossible because of organizational constraints related to the influx of patients into the department. We were therefore able to obtain only 10 IDU patients. To limit the heterogeneity of the ICU patient group and to be able to compare it with the IDU group, we decided to take into account for analysis patients who entered the ICU directly and patients who entered the ICU with prior admission to another department for a period < 3 days, but no patients from an ICU of another hospital. This reduced our Wave 1 ICU group to a total of 25 patients but did not impact the Wave 2 ICU group (see flow chart in Fig. 1).

2.2. Ethics

All patients or their relatives received fair and relevant information. They gave written informed consent for the storage and research use of residual blood from samples collected as part of routine care (IRB n° E20.20.56342 from CPP-Ile-de-France VI Groupe Hospitalier Pitié-Salpétrière). Blood samples from voluntary healthy donors were collected during the COVID-19 pandemic and then included as negative controls. Their demographics are given in Table 1.

2.3. Analysis of HLA-DR expression on monocytes

Monocyte HLA-DR (mHLA-DR) expression, in numbers of antibodies bound per monocyte (Ab/cell), was analysed at three time points, on days 0-3, days 7-10 and at ICU discharge (endpoint). EDTA-blood was drawn at the above time points after inclusion of patients in the study. The blood was stored at 4-8°C and processed within 4 h after withdrawal. The quantitative expression of mHLA-DR was determined with the anti-HLA-DR-anti-Monocyte QuantiBRITE assay (BD Biosciences, San Jose, CA, USA). Briefly, whole blood (25 μL) was stained with 10 μL of QuantiBRITE HLA-DR/Monocyte mixture (QuantiBRITE anti–HLA–DR PE (clone L243)/anti–monocytes (CD14) PerC–Cy5.5 (clone M6P9)), Becton Dickinson San Jose, CA, USA) at room temperature for 30 min in a dark chamber. Samples were then lysed using the FACS Lysing solution (Becton Dickinson San Jose, CA, USA) for 15 min. After a washing step, cells were analysed on a BD LSR II cytometer (BD Biosciences, San Jose, CA, USA) and flow data were analysed with FlowLogic software (version 7.3 software,Miltenyi Biotec, Germany). The total number of antibodies bound per monocyte (Ab/cell), defined as total CD14+ cells, were quantified by calibration with a standard curve determined with BD QuantiBRITE phycoerythrin (PE) beads (BD Biosciences, San Jose, CA, USA) (see Figure S1 for gating strategy). Antibodies, reagents and the respective suppliers are shown in Supplemental Table 1.

2.4. Plasma cytokine analysis

Plasma was obtained through centrifugation of EDTA samples within 4 h of phlebotomy at the indicated time points following inclusion of patients in the study. Plasma was placed in aliquots and stored at –20°C until use. Human pro-inflammatory cytokometric bead array (CBA) and human IFN-α flex kits (BD Biosciences, San Jose, CA, USA) were used. The human pro-inflammatory cytokine kit simultaneously detects IL-6, IL-10 and CXCL8 cytokines in a single sample whereas the IFN-α flex kit detects IFN-α. The assays were performed according to the manufacturer’s instructions. Samples and standards were acquired on the BD LSR II cytometer (BD Biosciences, San Jose, CA, USA) and the generated FSC files were analysed with FCAP Array version 3.0 software.

Plasma IL-1Ra levels were measured with a commercial enzyme-linked immunoassay (ELISA) kit (human IL-1Ra ELISA from Invitrogen, Villebon-sur-Yvette, France). Plasma samples were frozen and stored for batch analysis. In brief, to determine IL-1Ra levels, samples were thawed and 50 μL aliquots were incubated in microtitre wells coated with anti-human IL-1Ra antibody. The wells were then washed and detection achieved by adding biotin-conjugated anti-human IL-1Ra antibody followed by incubation with streptavidin-HRP, and finally by addition of horseradish peroxidase (HRP) substrate solution. A coloured product formed in proportion to the amount of human IL-1Ra present and absorbance was measured at 450 nm. Reagents and the respective suppliers are depicted in Supplemental Table 1.

2.5. Statistics

Statistical analyses and graphical presentations were conducted with GraphPad Prism version 8.0 software (Graph-Pad Software). The population was expressed as numbers and percentages for categorical variables. For quantitative variables, the results were expressed in terms of mean ± standard deviation in the Figures or mean and IC95 in the Tables. Categorical data were analysed with Chi-square test with a 5% risk of type 1 error. Statistical analysis of continuous variables, ie the different severity groups, mild versus severe forms, survivors versus non-survivors, was performed with one-way Mann–Whitney U test. For the longitudinal follow-up of patients, statistical analysis from baseline was performed with a Wilcoxon matched pairs test. Pearson’s correlation coefficient was used to assess the relationship between the PaO2/FiO2 ratio and mHLA-DR expression or IL-6 and mHLA-DR expression. Analyses were performed with no correction for multiplicity. The receiver operating characteristics (ROC) curve analysis was performed using the “pROC” package on R software to identify the optimal cut-off values of baseline and D7-10 mHLA-DR, IL-6 or IL-6/mHLA-DR $10^3$ parameters for prediction of fatal COVID-19 or secondary infections. The optimal cut-off points to predict the severity of COVID–19 were determined by Youden’s index using R software. Sensitivity, specificity and the corresponding IC95 of optimal cut-off points were determined using the “pROC” package.

2.6. Role of funders

None. The study was based on routine care and received no financial sponsorship.

3. Results

3.1. Cohort of consecutive patients

A total of 134 patients who were laboratory-confirmed to be infected with SARS-CoV-2 in hospital were included. The immunological characteristics and their clinical and laboratory features were compared between 124 severe cases admitted to the ICU and 10 mild cases admitted to the IDU (Table 1). ICU patients were more often men and were older than IDU patients. They also had a more severe inflammatory profile induced by COVID-19 as evidenced by a much
| Total ICU (n = 124) | ICU (n = 25) Wave 1 | ICU (n = 99) Wave 2 | P value Wave 1 vs Wave 2 | IDU (n = 10) | P value Total ICU vs IDU | Healthy controls (n = 11) | Reference range |
|---------------------|---------------------|---------------------|--------------------------|-------------|--------------------------|--------------------------|-----------------|
| Male – no. (%)      | 89 (71.2)           | 16 (64.0)           | 73 (77.4)                | 0.333       | 4 (40.0)                 | 0.030                    | 4 (36.4)        |
| Age – years         | 68.0 (65.8 – 70.0)  | 66.4 (62.3 – 70.5)  | 68.4 (66.0 – 70.7)       | 0.092       | 59.0 (49.2 – 68.8)       | 0.010                    | 34 (32 – 41)    |
| BMI – kg/m²         | 30.5 (29.2 – 31.7)  | 30.0 (27.2 – 32.8)  | 30.5 (29.2 – 31.9)       | 0.407       | 28.4 (25.7 – 31.0)       | 0.104                    | 20.6 (19.6 – 22.9) |
| Hypertension – no. (%) | 70 (56.5)         | 13 (52.0)           | 57 (57.6)                | 0.615       | 4 (40.0)                 | 0.314                    | 0 (0)           |
| Diabetes – no. (%)  | 45 (36.3)           | 8 (32.0)            | 37 (37.3)                | 0.618       | 4 (40.0)                 | 0.815                    | 0 (0)           |
| Cancer – no. (%)    | 21 (16.9)           | 5 (20.0)            | 16 (16.1)                | 0.648       | 1 (10.0)                 | 0.562                    | 0 (0)           |
| Laboratory findings |                     |                     |                          |             |                          |                          |                 |
| Lymphocytes – /mm³  | 921 (750 – 1091)    | 807 (689 – 956)     | 931 (734 – 1128)         | 0.363       | 1393 (1014 – 1771)       | <0.001                   | -               |
| Monocytes – /mm³    | 506 (285 – 640)     | 540 (220 – 900)     | 516 (436 – 595)          | 0.406       | 351 (273 – 430)          | 0.103                    | -               |
| CRP – mg/L          | 115.1 (100.3 – 129.8) | 146.8 (111.8 – 181.8) | 110.2 (93.8 – 126.7)     | 0.276       | 67.8 (47 – 109)          | 0.070                    | <5              |
| C3 – g/L            | 1.3 (1.1 – 1.4)     | 1.3 (1.1 – 1.4)     | 1.3 (1.1 – 1.4)          | 0.429       | -                        | -                       | 0.81 – 1.57     |
| C4 – g/L            | 0.4 (0.3 – 0.4)     | 0.3 (0.2 – 0.3)     | 0.4 (0.4 – 0.5)          | <0.001      | -                        | -                       | 0.13 – 0.39     |
| CH50 – U/ml         | 74.6 (71.6 – 77.5)  | 75.2 (66.7 – 83.8)  | 74.0 (71.8 – 76.2)       | 0.202       | -                        | -                       | 41.7 – 95.1     |
| Serum ferritin – μg/ml | 1520.7 (1227.3 – 1814.2) | 3279.2 (1860.7 – 4697.8) | 1338.8 (1101.1 – 1576.6) | 0.023       | 590.7 (297.7 – 1151.6)   | 0.070                    | -               |
| D-Dimers - ng/ml    | 2024.6 (1690.7 – 2439.4) | 2787.3 (1899.9 – 3674.8) | 1828.0 (1365.6 – 2290.4) | 0.001       | 1388.8 (318.1 – 2459.4)  | 0.081                    | <500            |
| IL-6 – pg/ml        | 243.7 (33.3 – 484.0) | 837.3 (265.6 – 1940.1) | 93.8 (9.8 – 197.3)       | <0.001      | 125.9 (9.7 – 15.3)       | <0.001                   | 1.6 (0.5 – 3.7) |
| CXCL8 – pg/ml       | 46.8 (29.8 – 63.8)  | 81.2 (27.6 – 134.7) | 38.1 (22.0 – 54.3)       | <0.001      | 23.2 (15.4 – 31.0)       | <0.001                   | 3.7 (2.7 – 4.7) |
| IFN-γ – pg/ml       | 8.4 (2.9 – 13.8)    | 17.7 (6.2 – 29.3)   | 7.4 (1.3 – 11.3)         | 0.020       | 8.8 (1.4 – 16.2)         | 0.217                    | 1.2 (0.1 – 2.2) |
| IL-10 – pg/ml       | 6.1 (3.9 – 8.3)     | 11.3 (1.6 – 21.0)   | 4.8 (3.7 – 6.0)          | 0.012       | 2.5 (1.5 – 3.6)          | 0.004                    | 0.8 (0.2 – 1.4) |
| IL1Ra – pg/ml       | 552.0 (386.9 – 717.3) | 1284.1 (615.2 – 1953.1) | 492.3 (332.7 – 652.0)   | 0.008       | 86.6 (66.1 – 107.1)      | 0.011                    | -               |
| mHLA-DR – pg/ml     | 11600 (10436 – 12764) | 5926 (5028 – 6824) | 11772 (10468 – 13076)   | 0.033       | 21566 (18004 – 25128)    | 0.010                    | 44544 (26884 – 62203) |
| Data are expressed as mean [IQR] or percentages (%). ICU: Intensive care unit; IDU: Infectious disease unit; BMI: Body mass index; CRP: C-reactive protein; C3, C4, CH50: Complement fractions; ARDS: Acute respiratory distress syndrome; SAPS II: Simplified Acute Physiology Score II. |
higher increase in serum ferritin and CRP and a statistically significant decrease in lymphocyte cell counts (Table 1). Thirty seven patients (30.6%) in the ICU as against none in the IDU developed a microbiologically-proven secondary infection, including 20 septic shocks (16.1%). Finally, 35 patients (28.2%) died in the ICU whereas all IDU patients recovered and were discharged (Table 1). Patient demographic characteristics on admission were not statistically different between the two waves of hospitalization. However, patients from Wave 1 were in a more severe condition than Wave 2 patients, as shown by higher CRP, D-Dimers and serum ferritin, associated with higher SAPSII scores, a longer length of stay in intensive care and the occurrence of statistically more secondary infections (Table 1). Medication and medical care administered to all ICU patients are given in Table S2. Overall mortality decreased in Wave 2, but not to a degree of significance.

3.2. COVID-19-induced inflammation at different times of ICU hospitalization

Upon admission, plasma concentrations of IL-6 and CXCL8 were statistically higher in patients who were primarily admitted to the ICU than in those admitted to a conventional IDU ward, whose concentrations were nevertheless statistically higher than those of the healthy controls (Table 1). In addition, changes in the management of ICU patients from June 2020 resulted in several modifications to pro-inflammatory cytokines. Specifically, Wave 1 patients, who were primarily admitted to the ICU up to March 2020, had a significant 8.9-fold increase in mean IL-6 values (837.3 pg/mL) compared to ICU patients from Wave 2 (93.8 pg/mL) (Table 1). Also, mean CXCL8 concentrations were significantly 2.1-fold higher in Wave 1 ICU patients (81.2 pg/mL) than in Wave 2 ICU patients (38.1 pg/mL). No statistically significant difference in IFN-α values was observed between IDU and ICU patients, but the initial mean IFN-α level of Wave 1 ICU patients was statistically higher than in Wave 2 ICU patients (Table 1).

Interestingly, 3.2% (n = 4/124) of ICU patients developed a condition compatible with CSS, whose threshold was defined as the mean of plasma cytokine concentrations + 2 SD by Mudd et al. [24]. Of these patients, 3 were from Wave 1 (12%, n = 3/25) and only one from Wave 2 (1%, n = 1/99) (p = 0.01, Fisher’s exact test) (Table S3). All but one of these patients died. None of these patients had a ferritin level greater than 4420 ng/mL (data not shown). The only survivor had been treated with tocilizumab, which produced a progressive decline in plasma IL-6 (data not shown). Finally, plasma IL-6 and the PaO2/FiO2 ratio at admission were well inversely associated in Wave 1 patients (r = -0.49) but weakly inversely correlated in Wave 2 patients (r = -0.16, Fig. 2a). Plasma IL-6 (p = 0.02, Mann–Whitney U test), but not CXCL8 (p = 0.2567, Mann–Whitney U test) values at admission were statistically higher in ICU COVID-19 patients with PaO2/FiO2 ratio less than 100 compared to others (Figure S2).

We re-analysed the cytokine results on admission no longer by grouping the patients by wave but depending on whether they had received corticosteroids or not. This confirmed that blood levels of pro-inflammatory cytokines were statistically lower in patients who had received corticosteroids (Figure S3). We next focused on hospitalized ICU patients, monitoring their cytokine profile over time according to disease outcome, fatal or not. The mean IL-6 level of Wave 2 survivor patients hospitalized in the ICU dropped from 33.4 pg/mL at admission to 11.3 pg/mL at discharge, which represents a statistically significant decrease from baseline (p = 0.003, Mann–Whitney U test), and reached IDU values (dotted grey line in Fig. 2b). The mean CXCL8 concentration of
survivor patients was 29.1 pg/mL at admission, 38.2 pg/mL at day 7-10, and 19.0 pg/mL at discharge: it decreased over time and was below IDU values at ICU discharge (dotted grey line in Fig. 2b). We chose to focus on the patients of Wave 2 because there were markedly more of them. Changes in CXCL8 levels over time had a fairly close profile in Wave 1 patients, but IL-6 levels remained stable (Figure S4). We divided non-survivors into two groups, one in which patients died less than 5 days after ICU entry and therefore had no second sample taken on days 7-10, and the other for deaths occurring later. Remarkably, the 4 patients who died early had much higher plasma IL-6 and CXCL8 concentrations at baseline than other deceased ICU patients (Fig. 2b). The other non-survivor patients had statistically higher plasma IL-6 and CXCL8 concentrations at baseline than other deceased ICU patients (Fig. 2b). The other non-survivor patients had statistically higher plasma IL-6 and CXCL8 concentrations (mean IL-6 = 52.8 pg/mL, mean CXCL8 = 33.0 pg/mL) at baseline (p = 0.008 and p = 0.009, respectively, Mann–Whitney U test) and on days 7-10 (p < 0.0001 and p = 0.006, respectively, Mann–Whitney U test) than survivor patients, with a statistically significant increase over time until death (p = 0.0108 for IL-6 and p = 0.0007 for CXCL8, Wilcoxon matched pairs test, Fig. 2b). The IFN-α levels of survivors decreased over time, starting at 5.6 pg/mL at admission and reaching 0.1 pg/mL at discharge, below IDU values (dotted grey line in Fig. 2b). The initial high IFN-α levels of non-survivor patients decreased over time to below-normal values at death (Fig. 2b). Finally, plasma IL-6 concentrations and PaO2/FiO2 ratio measured at all time points were significantly inversely correlated (r = -0.25, data not shown).

3.3. Severe COVID-19 diseases showed biological signs of immunosuppression

Upon admission, plasma concentrations of IL-10 were statistically higher in patients who were admitted to the ICU than those of patients admitted to conventional units, which in turn were statistically higher than those of healthy controls (Table 1). In addition, Wave 1 patients had a 2.4-fold significant increase in mean IL-10 concentrations (11.3 pg/mL) compared to ICU patients from Wave 2 (4.8 pg/mL) (Table 1). Notably, plasma IL-1Ra levels at admission were also statistically higher in ICU patients than in IDU patients, and Wave 1 ICU patients had a 2.6-fold significant increase in mean
concentrations of this cytokine (1284.1 pg/mL) compared to ICU patients from Wave 2 (492.3 pg/mL) (Table 1).

In contrast, mHLA-DR expression was dramatically lower in COVID-19 patients upon admission than in healthy controls and was statistically decreased by two fold in ICU patients compared to IDU patients (Table 1). In addition, ICU patients from Wave 1 had a statistically lower expression of mHLA-DR than Wave 2 patients (Table 1). Finally, mHLA-DR expression and PaO2/FiO2 ratio measured at admission were significantly correlated (Fig. 2a). Plasma IL-10 values at admission were non-significantly higher (p = 0.1043, Mann–Whitney U test) but mHLA-DR expression significantly decreased (p < 0.001, Mann–Whitney U test) in ICU COVID-19 patients with PaO2/FiO2 ratio less than 100 than in other patients (Figure S2).

Among ICU hospitalized patients, IL-10 concentrations in survivors decreased over time (Fig. 2c), starting at 3.6 pg/mL at admission and reaching 2.0 pg/mL at discharge (p = 0.0407, Mann–Whitney U test), close to IDU values (dotted grey line in Fig. 2c). Conversely, non-survivors had statistically higher plasma IL-10 concentrations at baseline (mean IL-10 = 8.6 pg/mL) than did survivors, which remained higher on days 7-10 but without change over time (Fig. 2c). There was no difference in IL-10 values at admission between patients who died early and those who died later. Data from Wave 1 yielded the same observations (Figure S4).

The mean mHLA-DR expression of survivor patients hospitalized in the ICU was 12,414 Ab/monocyte at admission, 8,783 Ab/monocyte on days 7-10, and 17,069 Ab/monocyte at discharge, with an increase over time (p = 0.0081, Wilcoxon matched pairs test Fig. 2c). Non-survivors had significantly down-regulated mHLA-DR expression at baseline (mean = 9644 Ab/monocytes) compared to survivors (p = 0.0171, Mann–Whitney U test). There was no difference in mHLA-DR expression on admission between patients who died early and those who died later. The difference between survivors and non-survivors was significantly accentuated on days 7-10 (p < 0.0001, Mann–Whitney U test), with expression of mHLA-DR in the latter group decreasing to 4,325 Ab/monocyte on average (p = 0.0004, Wilcoxon matched pairs test Fig. 2c). Finally, expression of mHLA-DR and PaO2/FiO2 ratio measured at all time points were significantly correlated (r = 0.33, data not shown).

3.4. Severe COVID-19 patients had both cytokine inflammation and monocyte dysregulation

In Wave 2 COVID-19 ICU patients, blood mHLA-DR expression and plasma IL-6 levels were significantly inversely well correlated at all time points (Fig. 3a). To simultaneously analyse both facets of the immune response, we performed an IL-6/mHLA-DR*10^3 ratio analysis. Survivor ratio was 3.4 at admission, 4.1 on days 7-10, and 0.89 at discharge, with a decrease over time to reach IDU values at ICU discharge (dotted grey line in Fig. 3b). Remarkably, the 4 patients who died early had a much higher IL-6/mHLA-DR*10^3 ratio at baseline (ratio of 185.0) than other deceased ICU patients (Fig. 3b). The other non-survivor patients had a statistically higher IL-6/mHLA-DR*10^3 ratio at baseline (ratio of 6.6) and on days 7-10 (ratio of 110.5) than survivor patients, with a very significant increase over time until death (Fig. 3b).

The ROC curve analysis identified the optimal cut-off values of baseline and D7 mHLA-DR, IL-6 or IL-6/mHLA-DR*10^3 parameters for prediction of fatal COVID-19 (Fig. 4, Table 2). These optimal cut-off points showed high negative predictive values (NPV) for the different parameters ranging from 86% to 100%. We also determined for the different parameters the thresholds that yielded positive predictive values (PPV) of 100% in order to identify patients at high risk of death (Table 2).

3.5. Inflammation and monocyte dysregulation in ICU COVID-19 patients with secondary infections

Secondary infections occurred in 26 out of 99 Wave 2 COVID-19 ICU patients. The microbiological data of those infections are given in supplemental Table S4. On admission, COVID-19 ICU patients who had experienced a secondary infection during their stay were significantly more inflammatory than those who had not, as evidenced by a 10-fold increase in plasma IL-6 during both waves (Fig. 5a). At the same time, these patients also had significantly down-regulated mHLA-DR expression during Wave 2, from 12,880 to 8,726 molecules per monocyte (Fig. 5b). Secondary infected patients had statistically increased IL-6/mHLA-DR*10^3 ratio values compared to non-secondary infected patients in both waves, resulting in 53-fold change and 9-fold change increases, respectively, for Wave 1 and Wave 2 (Fig. 5c). In Wave 2, 13 patients out of 26 who experienced a secondary infection developed a life-threatening infection and died (Table S4).

The ROC curve analysis identified the optimal cut-off values of mHLA-DR, IL-6 or IL-6/mHLA-DR*10^3 parameters for prediction of the occurrence of secondary infection (Figure S5, Table S5). These optimal cut-off points showed PPV of 100% at baseline for the different parameters and PPV ranging from 64% to 100% on days 7-10.

We divided the ICU patients with a secondary infection into two groups, one with early infections occurring within less than 3 days after ICU admission and another for infections that occurred more than 4 days after admission. Remarkably, IL-6 plasma levels in patients with early secondary infections (mean IL-6 = 558.2 pg/mL)
were not statistically different from those in patients with later infections (mean IL-6 = 53.3 pg/mL) (Fig. 5d). A notable exception was one Wave 2 patient who experienced a cytokine storm with IL-6 values at admission of 4981 pg/mL, which was 88 times higher than the median assay of the early infection group to which he belonged. Conversely, the levels of mHLA-DR were statistically different between the two groups of patients, with a two-fold downregulation in those with early secondary infections (Fig. 5e). Specifically, 26 ICU patients had at least one severe secondary infection in Wave 2. Of the 9 who developed early infections, all had an initial mHLA-DR lower than 9,000 Ab/monocyte (Table S6). Conversely, 10 out of 17 (59.0%) other patients who developed later infections after admission had initial mHLA-DR expression greater than this threshold. Likewise, we observed a difference in the IL-6/mHLA-DR ratio between the two groups, with about a 2-fold increase in the median in patients with early infection (Fig. 5f). In patients who developed infections 4 days after ICU admission, mHLA-DR expression recorded on days 7-10, ie near the onset of secondary infections, was statistically lower than that at admission and reached the mHLA-DR value obtained for ICU patients who presented early infections on days 0-3 (Fig. 5g). The lack of data on mHLA-DRs expression during Wave 1 prevented us from distinguishing between the relative impacts of IL-6 and mHLA-DR on the occurrence of secondary infections. However, it is important to emphasize that, as for the patient with a cytokine storm syndrome (CSS) in Wave 1 had secondary infections. There is therefore an over-representation of infections of this type in the CSS ICU patient group compared to non-CSS ICU patients (3/3 = 100% vs 9/22 = 40.9%).

4. Discussion

Patients with severe forms of COVID-19 have mortality rates in the ICU which remain high to this day. They most often die of respiratory failure after the development of ARDS. However, other factors may be associated with an increased risk of death, including secondary infections. Based on what we knew and practised in the context of sepsis, we hypothesized that severe COVID-19 patients were likely to suffer from a complex immune dysfunction combining inflammation and immunosuppression.

In our series, the plasma IL-6 and CXCL8 levels in the different severity groups of COVID-19 patients were statistically different on admission. This is clear evidence that severe ICU COVID-19 patients were experiencing inflammation. The cytokine results were also inversely correlated with the PaO2/FiO2 ratio, attesting to a link between the degree of inflammation and the pulmonary involvement of ARDS. Thus, in our series, as in other previous studies, the degree of initial inflammation appears to be predictive of the severity of COVID-19, both in terms of the severity of the lung injury and of the risk of death [3,10,12,25]. However, in agreement with recent data

---

**Table 2**

| Laboratory tests | Optimal cut-off | Sp - % (CI95) | Se - % (CI95) | Npv - % | Ppv - % |
|------------------|-----------------|---------------|---------------|---------|---------|
| **Younen’s index** | | | | | |
| mHLA-DR (D0-3) - Ab/c | 11312.5 | 54 (43 - 65) | 74 (57 - 91) | 87 | 34 |
| mHLA-DR (D7-10) - Ab/c | 4672.5 | 86 (71 - 96) | 75 (50 - 94) | 86 | 75 |
| IL-6 (D0-3) - pg/mL | 19.1 | 58 (47 - 70) | 91 (78 - 100) | 95 | 41 |
| IL-6 (D7-10) - pg/mL | 14.3 | 57 (39 - 75) | 100 (100 - 100) | 100 | 57 |
| IL-6 / mHLA-DR *10^3 (D0-3) | 1.4 | 56 (44 - 66) | 96 (87 - 100) | 98 | 41 |
| IL-6 / mHLA-DR *10^3 (D7-10) | 2.7 | 68 (50 - 86) | 100 (100 - 100) | 100 | 64 |
| **Maximum PPV = 100%** | | | | | |
| mHLA-DR (D0-3) - Ab/c | 2795.5 | 100 | 4.3 (0 - 13) | 77 | 100 |
| mHLA-DR (D7-10) - Ab/c | 1361.0 | 100 | 6.3 (0 - 19) | 65 | 100 |
| IL-6 (D0-3) - pg/mL | 226.7 | 100 | 13 (0 - 30) | 78 | 100 |
| IL-6 (D7-10) - pg/mL | 236.1 | 100 | 38 (13 - 63) | 74 | 100 |
| IL-6 / mHLA-DR *10^3 (D0-3) | 18.1 | 100 | 22 (4 - 40) | 80 | 100 |
| IL-6 / mHLA-DR *10^3 (D7-10) | 49.6 | 100 | 38 (13 - 63) | 74 | 100 |
| **Maximum Npv = 100%** | | | | | |
| mHLA-DR (D0-3) - Ab/c | 19081.0 | 17 (8 - 26) | 100 | 100 | 28 |
| mHLA-DR (D7-10) - Ab/c | 12615.0 | 25 (10 - 43) | 100 | 100 | 43 |

Sp: Specificity; Se: Sensitivity; NPV: Negative predictive value; PPV: Positive predictive value, CI95: Confidence interval 95%
from the literature and with our own (not shown), it is noteworthy that the mean values of these cytokine levels were much lower than in other pathological settings, such as bacterial septic shocks, other causes of ARDS or injections of CAR T cells, and quite close to levels induced by classical viral respiratory infections like in influenza [15–17,24]. In contrast to prevailing hypotheses about the pathophysiology of COVID-19 disease very few patients in our series presented cytokine profiles indicative of CSS. In the absence of any internationally recognized criterion we set the threshold according to the method recently described by Mudd et al., which indicated that only 4 of our COVID-19 patients had CSS [24], all of whom were hospitalized in the ICU and none in the IDU. Although cases of CSS were rare in our patient series they nevertheless made up a severe subgroup with a very poor prognosis, since 3 out of the 4 patients who met the criterion on admission died during hospitalization, a mortality rate of 75% compared to an overall mortality in ICU patients of 25%. Note that for the 3 patients for whom we had a ferritin assay, none reached the threshold of 4420 ng/mL, previously used for evoking a macrophage activation syndrome during COVID-19 [21].

Another interesting point among ICU patients was the dramatic decrease in proinflammatory cytokines measured during Wave 2 compared to Wave 1. In particular, 12% of patients met the criteria for CSS during Wave 1 as against 1% during Wave 2. These results show that CSS, and hence hyperinflammation, was not that rare during Wave 1 but much more so during Wave 2. They should be put in perspective with the significant change in management practices introduced in our teaching hospital between the two waves. Following the publication in July 2020 of the RECOVERY trial, the great majority of patients in Wave 2 received dexamethasone (89%) compared to a small minority in Wave 1 who had received corticosteroids (5/25, ie 20% of patients receiving between 10 and 60 mg of prednisone per day) [23]. One of the main known pharmacological mechanisms of the action of glucocorticoids is to inhibit the synthesis of pro-inflammatory cytokines [26]. It makes sense to think that the decrease in cytokine levels that we saw in Wave 2 was due to the almost systematic use of this molecule. However, to our knowledge, we are the first to demonstrate this in comparative data [27].
To assess whether COVID-19 induced monocyte dysregulation, we required a test that was both able to test a key functionality of the immune system and routinely available. Our choice quickly fell on the membrane expression of HLA-DR on blood monocytes. Low mHLA-DR has become one of the best markers of monocyte immunosuppressive phenotype in various diseases such as cancers and sepsis [22,28–31]. The scientific rationale for these findings, from a fundamental immunological point of view, is that HLA-DR is the main antigen-presenting molecule for helper T cells on the surface of monocytes, macrophages and dendritic cells. Thus, it is assumed that the decrease in mHLA-DR on the surface of blood monocytes is a reflection of a reduced overall capacity for presenting antigens and therefore for inducing adaptive immune responses. The anomalies of the myeloid compartment induced by COVID-19 are being gradually documented, in particular those concerning monocytes, with early expansion and activation of blood classical CD14+ monocyte expressing HLA-DR+ being seen in moderate COVID-19 patients and conversely an accumulation of mHLA-DRlo monocytes in severe patients [11,23,24,26,27]. All these data confirm the potential interest of the marker of monocyte immunosuppressive phenotype that we chose [32–34].

In our series, on the basis of recognized interpretation thresholds from the literature for the analysis of mHLA-DR expression, it can be considered that IDU patients with mild forms, despite having lower values than healthy controls, are not immunosuppressed on admission (mean HLA-DR = 21566 Ab/cells) unlike ICU patients, who clearly are [20,31,35,36]. Hence, as previously reported, decreased mHLA-DR was a significant predictor of COVID-19 disease severity [24,37,38]. In our study, levels of IL-10, one of the main anti-inflammatory cytokines, were statistically higher in ICU patients than in IDU patients and healthy controls. In addition, concentrations of IL-1Ra, a cytokine of the acute phase of inflammation which plays an anti-inflammatory role of counter-regulation, in particular at the level of monocytes (both target and producer of the molecule), were also statistically higher in ICU patients than in IDU patients. The profile of secretion of these two molecules therefore confirmed, in agreement with mHLA-DR data, the presence of immunosuppression in the most severe patients.

Comparison of the results of ICU patients between the two waves showed that patients in Wave 1 expressed monocyte mHLA-DR significantly less than those in Wave 2. On the basis of the same criteria as before, Wave 1 patients exhibited severe monocyte dysregulation, on the verge of immunoparalysis (mean HLA-DR = 5926 Ab/cells) unlike Wave 2 patients, who were in a state of simple monocyte dysregulation (mean HLA-DR = 11772 Ab/cell). Here again, IL-10 and IL-1Ra levels were in close agreement with mHLA-DR results, with Wave 1 ICU patients showing higher concentrations of both immunosuppressive cytokines. One could suspect again that systematic treatment with dexamethasone played a role [39,40].

Comparison of the mHLA-DR data in the different groups of COVID-19 patients on ICU admission according to mortality showed that the expression of the marker was inversely proportional to the severity of the disease. The time-dependent evolution of mHLA-DR should be emphasized because in the two groups of patients, survivors and non-survivors, a statistically significant decrease in values was observed on days 7-10 compared to baseline. However, the difference in values between the two groups increased statistically, with surviving patients remaining in the zone of simple monocyte dysregulation while those in the non-survivor group became severely immunosuppressed [31,35]. Subsequently, in surviving patients, a statistically significant increase in measurements was observed before ICU discharge, with values returning to normal, thereby indicating the disappearance of monocyte dysregulation. It can thus be considered that the evolution of mHLA-DR follows a V trend curve, as recently reported, with a nadir probably between days 7 and 10 after ICU admission when immunosuppression is therefore probably at its greatest [41,42]. All these data show, for the first time to our knowledge, that the quantitative expression of HLA-DR on monocytes is a predictive marker of mortality in COVID-19 patients. They are to be compared with those of a previous study which found a decrease in the number of CD14+ HLA-DR+ monocytes in patients who died of COVID-19 compared to survivors [33]. In addition, mHLA-DR quantitative expression during hospitalization was also significantly correlated with the PaO2/FiO2 ratio thereby indicating, as previously described, a relation between the degree of monocyte dysregulation and the pulmonary involvement of ARDS [21]. Again, it is noteworthy that the IL-10 results are in agreement with those of mHLA-DR, notably with IL-10 levels being very significantly greater in the non-survivor group than in survivor patients. Thus, during severe COVID-19 infections, we found an immunosuppressive profile associating IL-10 production and a decrease in mHLA-DR the same as that already observed in septic shocks [43]. We could not evaluate it for reasons of simplicity and effectiveness contrary to our routine care approach, but we can hypothesize, given the data in the literature, that this result probably reflects a more overall myeloid (granulocytes, macrophages, dendritic cells) and lymphoid dysregulation which would be interesting to investigate in later studies.

Interestingly, we showed that IL-6 and mHLA-DR were well correlated in ICU patients, in an inversely proportional way. This enables us to assert that inflammation and monocyte dysregulation are indeed phenomena occurring concomitantly in patients with severe forms of COVID-19 and therefore confirm our initial hypothesis. Consequently, the use of the IL-6/mHLA-DR ratio could be of interest to simultaneously analyse the two aspects of the immune response in the same patient. In ICU patients, the ratio on admission was significantly higher in the non-survivor group than in the survivor group, and the difference was even more marked on days 7–10, confirming that the inflamed/immunocompromised dual state is associated with poor prognosis. The analysis of ROC curves for IL-6 concentrations, HLA-DR expression, and IL-6/mHLA-DR ratio on admission showed that IL-6/mHLA-DR ratio was the more reliable cut-off for predicting fatal outcome. Thus, we could propose the use of IL-6/mHLA-DR ratio in current clinical practice, with a threshold of 18, as in our series, to obtain a PPV of the risk of death of 100%. To our knowledge, this is the first report to demonstrate that IL-6/mHLA-DR ratio is a valuable marker for predicting death in COVID-19. This interesting result needs to be confirmed soon using the proposed threshold prospectively in studies involving a greater number of patients.

These results should be compared with those of recent studies suggesting that immune dysregulation during COVID-19 with early and prolonged immune system activation can result in cellular exhaustion [44]. More precisely, it has been proposed that severe COVID-19 patients suffered from a defective antigen-presentation, evidenced by a decrease in mHLA-DR and which, associated with lymphopenia, led to defective function of lymphoid cells, whereas monocytes remained potent for the production of TNFα and IL-6. Moreover, the involvement of IL-6 in the mHLA-DR decrease has been demonstrated in part by the fact that an IL-6 blocker, Tocilizumab, partially rescued this downregulation in vitro [21,45]. Our results could be considered as consistent with this observation. However, we cannot rule out a role for IL-10 as well since levels of the cytokine were also higher in our severe patients, and previous publications have shown its involvement in the internalization of HLA-DR molecules in monocytes in the context of septic shock [46]. Another factor that could contribute to the decrease in HLA-DR on monocytes was the involvement of neutrophil granulocytes. The role of the activation of these cells in COVID-19, which has been reported by various teams, seems to be corroborated in our study by the increase in CXCL8 levels in severe forms. In particular, the secretion of neutrophil elastase is associated with the severe forms of the disease [47,48]. However, once released this elastase has the property of lysing nearby HLA-DR molecules [49]. In our series, we observed an
increase in this marker in our most severe patients and an inverse correlation with the expression of HLA-DR (data not shown). However, these preliminary results need to be confirmed in other studies.

To demonstrate that the changes in our markers in severe COVID-19 forms, especially the decrease in HLA-DR on monocytes, were relevant functional indicators of immunoparesis of the immune system, we decided to correlate the occurrence of serious secondary infections over time with the expression of the markers to see if they were predictive of a risk of secondary infections in the short term. Although relatively unknown, it is very common for COVID-19 patients to develop secondary infections during ICU hospitalizations with several studies reporting superinfection rates higher than 50% [8,9]. The occurrence of secondary infections is also recognized as a clinical predictor of fatal outcome in COVID-19 cases [50]. In our study, we can see that 52% of total deaths from Wave 2 were directly attributable to severe secondary infections, which makes these infections the main cause of death in our patients. On admission, IL-6 concentrations, mHLA-DR expression, and IL-6/HLA-DR ratio were all statistically higher in patients who later developed a secondary infection at some point during their hospitalization. Conversely, when we compared the two groups of patients with early or later infections, the IL-6 values were at levels not statistically different. Interestingly, mHLA-DR expression was on the other hand statistically lower in the early infections group than in the group with later infections with a threshold differentiating between the two groups set empirically (because unfortunately we did not have enough points to set a threshold using interpretable ROC curves) at around 9000 Ab/monocyte. Of note, the group of patients with later infections downregulated mHLA-DR expression to less than this threshold on day 7, the moment when they in turn developed secondary infections. These results clearly demonstrate that the decrease in mHLA-DR expression, but not the slight increase in IL-6 levels, corresponds to an immunosuppression state correlated with the risk of the rapid occurrence of secondary infections. Finally, we show, for the first time to our knowledge, that the downregulation of HLA-DR on monocytes is a predictive marker of early secondary infections in COVID-19 patients. With regard to IL-6, the only patient who presented a major CSS during Wave 2 developed a very early secondary infection. Likewise, the 3 patients who had a cytokine storm during Wave 1 also developed early secondary infections. Unfortunately, HLA-DR expression was measured in only one patient, who was severely immunocompromised (3422 Ab/monocyte). Thus, patients with COVID-19-induced CSS in our study seem to be a subgroup at high risk for secondary infections. Cytokine storms therefore seem to be occurrences that associate massive inflammation and severe immunosuppression.

4.1. Caveats and Limitations

Among the main limitations of this study was the relatively small population size, in particular the healthy controls, IDU patients and Wave 1 ICU groups. This was in part due to the health situation during the first wave, when the partial saturation of our hospital created difficulties in organizing the samples, and stocks of certain cytometry reagents were in short supply. It should be noted that we have recently analysed 18 additional IDU patients. Interestingly, they exhibited an immune profile identical to that of the patients presented in this study (Figure S6). In particular, there was no significant difference between the values obtained for the two IDU groups for all parameters tested. These new patients were included from 11/17/2020 to 05/02/2021, a period in France corresponding to the occurrence of the third epidemic wave (with the introduction into the territory of the Alpha variant), and so we preferred not to pool their results with those of the initial group to avoid introducing too much heterogeneity between the patients. The results nevertheless give reassuring arguments as to the validity of our results for IDU patients.

Another limitation of our study, which is related to our decision to adopt a routine care approach, is that we assessed the degree of immunosuppression of patients on only three markers (mainly mHLA-DR) and did not perform complex multiparametric analyses to assess more extensively all the immune cell populations involved in the complex immune deregulation of COVID-19. In addition, direct conclusions on the causality between disease severity and immunological profiles and the use of dexamethasone cannot be drawn from our study due to its explorative nature. It would therefore be interesting to try a functional approach to test whether the monocytes of severe COVID-19 patients with downregulated mHLA-DR have altered properties, for example in terms of phagocytosis or cytokine synthesis in response to various stimuli, especially with regard to their possible mechanistic role in disease course and severity.

We plan to test these last three points in an ancillary study that we will carry out soon of new patients. Patient assignment to our cohort was not random but exclusively based on the notion of hospitalization. The introduction of bias due to this approach cannot be excluded as it is possible that because of their profile certain patients were not hospitalized in teaching hospitals or that particularly severe patients died before they could be hospitalized. The fact that there are very few intensive care beds in our region other than those at our hospital appears to minimize this risk. We are unable to protect against the risk of death before hospitalization and this is why we made mention of it earlier in the text.

Finally, in the analysis of disease severity, we classified the patients according to admission to ICU versus IDU wards, which might differ from classifications used in other studies. In line with numerous previous works, we observed a relationship between the degree of increase in proinflammatory markers and disease severity. Plasma sampling was performed at pre-defined time points depending on the day of hospital admission but it could be argued that difference in severity is attributable to longer disease duration. Nevertheless, while this may have been theoretically a potential confounder, the time from disease onset to hospital admission was recorded and showed no significant difference between the two ICU groups. To limit the heterogeneity of the ICU patient group and to be able to compare it with the IDU group, we decided to include for analysis only patients admitted directly to the ICU and those who were admitted after prior admission to another department for a period <3 days. As a consequence of our study’s pragmatic design, we performed no correction for other potential confounders, such as comorbidity, medication or invasive mechanical ventilation use.

In the future, personalized medicine approaches to COVID-19 and complete immunomonitoring simultaneously investigating both sides of the immune response will undoubtedly be taken into account to choose the most appropriate therapeutic interventions since they can be completely opposite (for example anti-IL-6 antibodies versus immune stimulants such as GM-CSF or IL-7) according to the patient’s profile [51,52]. Finally, owing to the use of simple routine care biological markers, our approach responds at least in part to the problem by making it possible to better characterize the profile of the immune response of patients with severe COVID-19 in terms of inflammation or immunosuppression. With the exception of a subgroup of very severe patients who experienced a major cytokine storm, the great majority of our hospitalized patients had moderate inflammation associated with severe monocyte dysregulation, which is predictive of the severity of the disease, its mortality and the risk of secondary infections.

Contributors

BE, BB and BS conceptualized and designed the study. BB, JC, LF, BE, EC, CD, CL, MA, MB, MV and LH conducted the investigations (recruiting patients or conducting laboratory tests). BB and BE conducted formal data analysis. BB and BE wrote the original first draft of manuscript. All authors reviewed the manuscript and gave
significant input, BB, BE, BS, and CD had access to and verified all underlying data. BB ensures data curation. The final version of this paper was reviewed and approved by all authors.

Data Sharing Statement

Individual participant data cannot be made available due to EU Data Protection Regulations (GDPR). A limited and completely anonymized version of the dataset can be obtained upon request. Laboratory protocols will be available upon request. Enquiries should be directed to bevrand@chu-clermontferrand.fr.

Declaration of Competing Interest

Dr. Bonnet reports non-financial support from THE BINDING SITE GROUP LTD, non-financial support from DIASORIN SA, non-financial support from Werfen, outside the submitted work. Prof. SOUWEINE reports personal fees from MSD, non-financial support from TTM BARD, personal fees from SANOFI, personal fees from LABORATOIRE AGUETANT, outside the submitted work. All other authors have no conflicts of interest to disclose.

Acknowledgements

We thank the promoters of the CORIMUNO-19 project (INSERM-Assistance Publique des Hôpitaux de Paris) for their help, the patients of our study for being part of this cohort (screening with signature of a consent without being included in the associated trials (due to competition with other studies in progress). We thank Xavier Daudet, Estelle, Chapon, Charline Pierson, Aurelie Brionch, Brigitte Goutte, Marlène Ravel, Julia Mercier, Marion Gaudard, Solène Reyv, Maud Junda and Frédéric Dueé for their immense assistance in the laboratory during patient material collection. Thank you to the entire staff of the Department of Infectious Diseases and intensive care unit for their feedback and scientific discussions. We thank the AFRRI association, who kindly provided the additional doses of IL-1ra. This study was not supported by any grant.

Supplementary material associated with this article can be found in the online version at doi: 10.1016/j.ebiom.2021.103622.

References

[1] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(11):1708-20.
[2] Verty R, Orell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020;20(6):669-77.
[3] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients with infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.
[4] Sheikh J, Ho KS, Poon J, Sarosky K, Fung JY. Palliative care in critically ill COVID-19 patients: the early New York City experience. BMJ Support Palliat Care 2020.
[5] Sims JT, Krishnan V, Chang C-Y, Engle SM, Casalini G, Rodgers GH, et al. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol 2020.
[6] Shima A, Buta K. Control of immunity by glucocorticoids in health and disease. J Intern Med 2020;42(6):669-80.
[7] Andreaes E, Papadaki M, Serhan CN. Cytokines, anti-inflammatory, pro-resolving lipid mediators and resolution of inflammation in COVID-19. Allergy 2020.
[8] Gujar JN, Rosenfeld D, Weisberg E, Sirlin CB, Davis KA, Rabinowitch-D'Amour C, et al. Abnormalities in immunoglobulin production, determining the role of cytokines in COVID-19 patients. JAMA Intern Med 2020;180(9):1152-4.
[9] Monneret G, Benlyamani I, Gossez M, Bermejo-Martín JF, Martín-Fernández M, Sespes P, et al. COVID-19: what type of cytokine storm are we dealing with? J Med Virol 2020.
[10] Hadjadj J, Yatim N, Barnabei L, Conneau A, Bousset J, Smith N, et al. Impaired type I interferon and inflammatory responses in severe COVID-19 patients. Science 2020;abab6027.
[11] Leitman DE, Ronner I, Pinotti R, Taylor MD, Sinha P, Callefs CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 2020;8(12):1233-44.
[12] Sinha P, Mathay MA, Callefs CS. Is a Cytokine Storm relevant to COVID-19? JAMA Intern Med 2020;180(9):1152-4.
[13] Monneret G, Benlyamani I, Gossez M, Bermejo-Martin JF, Martin-Fernandez M, Sespes P, et al. COVID-19: what type of cytokine storm are we dealing with? J Med Virol 2020.
[14] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[15] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[16] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[17] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[18] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[19] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[20] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[21] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[22] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[23] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[24] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[25] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[26] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[27] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[28] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[29] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[30] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[31] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
[32] Vabret N, Crawford J, Jackson SJ, Brencher CP, Kupper TS, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv 2020.
Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection. Cytometry A 2020;97(9):887-90.

Le Tulzo Y, Pagnault C, Amiot L, Guillon V, Tribut O, Arvieux C, et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 2004;169(10):1144-51.

Schwiebert LM, Schleimer RP, Radka SF, Ono SJ. Modulation of human cells by dexamethasone. Cell Immunol 1995;165(1):12-9.

Payen D, Gravat M, Maadadi H, Didelot C, Prosic L, Dupuis C, et al. A longitudinal study of immune cells in severe COVID-19 patients. Front Immunol 2020;11:580250.

Monneret G, Cour M, Viel S, Venet F, Argaud L. Coronavirus disease 2019 as a particular sepsis: a 2-week follow-up of standard immunological parameters in critically ill patients. Intensive Care Med 2020;46(9):1764-5.

Monneret G, Finck M-E, Venet F, Debard A-L, Bohé J, Bienvenu J, et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 2004;95(2):193-8.

Mudd PA, Remy KE. Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity? J Clin Invest 2020.

Janssen NAF, Grondman I, de Nooijer AH, Boahen CK, Koeken VACM, Matzaraki V, et al. Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19. J Infect Dis 2021;223(3):1322-33.

Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002;166(11):1475-82.

Guéant J-L, Guéant-Rodriguez R-M, Fromonot J, Oussalah A, Louis H, Chery C, et al. Elastase and exacerbation of neutrophil innate immunity are involved in multisystemic manifestations of COVID-19. Allergy 2021;76(6):1846-58.

Leppkes M, Knopf J, Naichberger E, Lindemann A, Singh J, Herrmann I, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 2020;58:102925.

Domon H, Maekawa T, Isono T, Furuta K, Kaito C, Teras Y. Proteolytic cleavage of HLA class II by human neutrophil elastase in pneumococcal pneumonia. Sci Rep 2021;11(1):2432.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(5):846-8.

Remy KE, Mazer M, Striker DA, Ellebedy AH, Walton AH, Unsinger J, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCIInsight 2020;5(17).

Andrianopoulos I, Papathanasiou A, Papathanakos G, Chaidos A, Koulouras V. Tocilizumab’s efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm. J Med Virol [Internet] 2020 [cited on Dec 9, 2020]; Available on: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361556/.